Matching variables used for all comparisons
Age As 5-year bins between 16 and 111 years
Sex Male or female
Vaccination status Not vaccinated; received a single-dose vaccine (i) <14 days before COVID-19 diagnosis; ii) 14-90 days before or (iii) >90 days before COVID-19 diagnosis; received the 1st dose of a two-dose vaccine (i) <14 days before; (ii) 14-90 days before or (iii) >90 days before COVID-19 diagnosis; received the 2nd dose of a two-dose vaccine (i) <14 days before; (ii) 14-90 days before or (iii) >90 days before COVID-19 diagnosis
Calendar period Up to January 9 2020 (including) – still no vaccination, Alpha strain(s) prevailing; January 10 – July 15 2021 – Alpha strain(s) prevailing, mass vaccination in progress; after July 15 2021 – Delta strain starts to prevail, mass vaccination in progress.
Comorbidities Charlson comorbidity index (CCI) subseted at 4 levels: 0, 1-2, 3-4 and ≥5, and also individual comorbidities: atrial fibrillation, autoimmune disease, malignant disease (cancer), congestive heart failure, chronic obstructive pulmonary disease, history of ischemic heart disease or a cerebrovascular disease, renal disease, diabetes without complications, diabetes with complications
Pharmacological treatments Inhibitors of the renin-angiotensine-aldosterone system (RAAS) (includes any of the following: angiotensine converting enzyme inhibitors, angiotensine receptor antagonists and mineralocorticoid receptor antagonists); diuretics (any)
Matching variables additionally used in the comparison between patients burdened with psychiatric difficulties that may require antidepressant/anxyolytic treatment, who were prescribed (Group A) and not prescribed (Group B) fluvoxamine (Group C by definition is free of such conditions) Matching variables additionally used in the comparison between patients burdened with psychiatric difficulties that may require antidepressant/anxyolytic treatment, who were prescribed (Group A) and not prescribed (Group B) fluvoxamine (Group C by definition is free of such conditions) Matching variables additionally used in the comparison between patients burdened with psychiatric difficulties that may require antidepressant/anxyolytic treatment, who were prescribed (Group A) and not prescribed (Group B) fluvoxamine (Group C by definition is free of such conditions)
Dementia Includes Alzheimer’s dementia (G30, F00), senile degeneration of the brain (G31.1), vascular dementia, dementia in other diseases classified elswhere and unspecified dementia (F01-F03), delirium superimposed on dementia (F05.1)
Mood disorders Mood (affective) disorders (F30-F39)
Nonpsychotic mood disorders Anxiety, dissiciative, stress-related, somatoform and other nonpsychotic mood disorders (F40-F48)
Substance use Mental and behavioral disorders due to psychoactive substance use (F10-F19)
Non-mood psychotic disorders Schizophrenia, schizotypal, delusional and other non-mood psychotic disorders (F20-F29)
Cumulatively: F50-F59, F60-F69, F70-F79, F80-F89, F90-F98, F04-F09 Behavioral syndromes associated with physiological disturbances and physical factors; Disorders of adult personality and behavior; Intellectual disabilities; Pervasive and specific developmental disorders; Behavioral and emotional disorders with onset in childhood and adolescence; mental disorders due to know physiological condition (F04,05,06, 07, 09).